Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
AMTD Digital ADR | HKD | Feb 5, 2025 | 2.65 | -1.12 |
AMTD Idea Group ADR | AMTD | Feb 5, 2025 | 1.03 | +1.98 |
Amtech Systems | ASYS | Feb 5, 2025 | 5.23 | -0.38 |
Amylyx Pharmaceuticals | AMLX | Feb 5, 2025 | 3.69 | +1.93 |
AN2 Therapeutics | ANTX | Feb 5, 2025 | 1.17 | +5.41 |
Analog Devices | ADI | Feb 5, 2025 | 209.80 | +1.84 |
AnaptysBio | ANAB | Feb 5, 2025 | 16.06 | -2.73 |
Anavex Life Sciences | AVXL | Feb 5, 2025 | 8.94 | +0.79 |
Andretti Acquisition II | POLE | Feb 5, 2025 | 10.05 | 0.00 |
Andretti Acquisition II Unit | POLEU | Feb 5, 2025 | 10.10 | 0.00 |
Anebulo Pharmaceuticals | ANEB | Feb 5, 2025 | 1.57 | +2.61 |
Angel Oak Financial Strategies | FINS | Feb 5, 2025 | 13.42 | -0.59 |
Angel Oak Mortgage REIT | AOMR | Feb 5, 2025 | 10.32 | +0.19 |
Anghami | ANGH | Feb 5, 2025 | 0.70 | -3.01 |
Angi A | ANGI | Feb 5, 2025 | 1.84 | +0.55 |
AngioDynamics | ANGO | Feb 5, 2025 | 10.89 | -0.82 |
Anglogold Ashanti | AU | Feb 5, 2025 | 31.98 | +3.63 |
Anheuser-Busch InBev ADR | BUD | Feb 5, 2025 | 49.11 | +0.84 |
ANI Pharmaceuticals | ANIP | Feb 5, 2025 | 59.81 | +2.08 |
Anika Therapeutics | ANIK | Feb 5, 2025 | 17.97 | +0.73 |
Anixa Biosciences | ANIX | Feb 5, 2025 | 3.00 | +1.01 |
Annaly Capital Management | NLY | Feb 5, 2025 | 20.54 | +0.20 |
Annaly Capital Management F Pref | NLY-F | Feb 5, 2025 | 25.80 | +0.23 |
Annaly Capital Management G Pref | NLY-G | Feb 5, 2025 | 25.39 | +0.20 |
Annaly Capital Management I Pref | NLY-I | Feb 5, 2025 | 25.74 | 0.00 |
Annexon | ANNX | Feb 5, 2025 | 3.70 | +0.27 |
Annovis Bio | ANVS | Feb 5, 2025 | 3.14 | 0.00 |
ANSYS | ANSS | Feb 5, 2025 | 347.01 | +0.01 |
Antelope Enterprise | AEHL | Feb 5, 2025 | 0.13 | +0.72 |
Anteris Technologies Global | AVR | Feb 5, 2025 | 6.20 | 0.00 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.